ACETAMINOPHEN AND CODEINE PHOSPHATE- acetaminophen and codeine phosphate tablet Stany Zjednoczone - angielski - NLM (National Library of Medicine)

acetaminophen and codeine phosphate- acetaminophen and codeine phosphate tablet

preferred pharmaceuticals, inc. - acetaminophen (unii: 362o9itl9d) (acetaminophen - unii:362o9itl9d), codeine phosphate (unii: gsl05y1mn6) (codeine anhydrous - unii:ux6owy2v7j) - acetaminophen and codeine phosphate tablets are indicated for the management of mild to moderate pain, where treatment with an opioid is appropriate and for which alternative treatments are inadequate. limitations of use because of the risks of addiction, abuse, and misuse, with opioids, even at recommended doses [see warnings ], reserve acetaminophen and codeine phosphate tablets for use in patients for whom alternative treatment options [e.g., non-opioid analgesics] acetaminophen and codeine phosphate tablets are contraindicated for: acetaminophen and codeine phosphate tablets are contraindicated in patients with: acetaminophen and codeine phosphate tablets contain codeine. codeine in combination with acetaminophen, a schedule iii controlled substance. acetaminophen and codeine phosphate tablets contain codeine, a substance with a high potential for abuse similar to other opioids, including fentanyl, hydrocodone, hydromorphone, methadone, morphine, oxycodone, oxymorphone, and tapentadol. acetaminophen and c

ALPRAZOLAM tablet Stany Zjednoczone - angielski - NLM (National Library of Medicine)

alprazolam tablet

preferred pharmaceuticals, inc. - alprazolam (unii: yu55mq3izy) (alprazolam - unii:yu55mq3izy) - anxiety disorders alprazolam tablets, usp are indicated for the management of anxiety disorder (a condition corresponding most closely to the apa diagnostic and statistical manual [dsm-iii-r] diagnosis of generalized anxiety disorder) or the short-term relief of symptoms of anxiety. anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. generalized anxiety disorder is characterized by unrealistic or excessive anxiety and worry (apprehensive expectation) about two or more life circumstances, for a period of 6 months or longer, during which the person has been bothered more days than not by these concerns. at least 6 of the following 18 symptoms are often present in these patients: motor tension (trembling, twitching, or feeling shaky; muscle tension, aches, or soreness; restlessness; easy fatigability); autonomic hyperactivity (shortness of breath or smothering sensations; palpitations or accelerated heart rate; sweating, or cold clammy hands; dr

Straumann RN Prosthetics Singapur - angielski - HSA (Health Sciences Authority)

straumann rn prosthetics

straumann group & clear correct singapore pte. ltd. - dental - the straumann rn prosthetics are intended to be used in conjunction with an endosseous dental implant fixture to aid in prosthetic rehabilitation

POSACONAZOLE JUNO posaconazole 100 mg modified release tablets blister pack Australia - angielski - Department of Health (Therapeutic Goods Administration)

posaconazole juno posaconazole 100 mg modified release tablets blister pack

juno pharmaceuticals pty ltd - posaconazole, quantity: 100 mg - tablet, modified release - excipient ingredients: colloidal anhydrous silica; triethyl citrate; microcrystalline cellulose; croscarmellose sodium; propyl gallate; methacrylic acid - ethyl acrylate copolymer (1:1); xylitol; sodium stearylfumarate; hyprolose; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350 - posaconazole juno is indicated for use in the treatment of the following invasive fungal infections in patients 13 years of age or older:,? invasive aspergillosis in patients intolerant of, or with disease that is refractory to, alternative therapy.,? fusariosis, zygomycosis, coccidioidomycosis, chromoblastomycosis, and mycetoma in patients intolerant of, or with disease that is refractory to, alternative therapy.,posaconazole juno is also indicated for the prophylaxis of invasive fungal infections among patients 13 years of age and older, who are at high risk of developing these infections, such as patients with prolonged neutropenia or haematopoietic stem cell transplant (hsct) recipients.

Specimen receptacle IVDs Australia - angielski - Department of Health (Therapeutic Goods Administration)

specimen receptacle ivds

rn labs pty ltd - ct936 - specimen receptacle ivds - the functional pathology specimen receptacles are specifically intended for the self-collection, preservation and transport of a specimen derived from the human body, (such as patient's cells, fluids and tissues), for the purposes of in vitro diagnostic examination at a laboratory.

Home blood collection kit Australia - angielski - Department of Health (Therapeutic Goods Administration)

home blood collection kit

rn labs pty ltd - 38092 - home blood collection kit - home blood collection kit for the collection and transport of a capillary blood sample for laboratory testing or screening purposes. a collection of sterile devices and materials intended to be used by a layperson to collect and mail the sample to a clinical laboratory for diagnostic testing or screening purposes.

DULOXETINE DELAYED-RELEASE- duloxetine hydrochloride capsule, delayed release pellets Stany Zjednoczone - angielski - NLM (National Library of Medicine)

duloxetine delayed-release- duloxetine hydrochloride capsule, delayed release pellets

preferred pharmaceuticals inc. - duloxetine hydrochloride (unii: 9044sc542w) (duloxetine - unii:o5tnm5n07u) - duloxetine delayed-release capsules are indicated for the treatment of: starting duloxetine delayed-release capsules in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome [see dosage and administration (2.9) and warnings and precautions (5.4)] . pregnancy category c risk summary — there are no adequate and well-controlled studies of duloxetine administration in pregnant women. in animal studies with duloxetine, fetal weights were decreased but there was no evidence of teratogenicity in pregnant rats and rabbits at oral doses administered during the period of organogenesis up to 4 and 7 times the maximum recommended human dose (mrhd) of 120 mg/day, respectively. when duloxetine was administered orally to pregnant rats throughout gestation and lactation, pup weights at birth and pup survival to 1 day postpartum were decreased at a dose 2 times the mrhd. at this dose, pup behaviors consistent with i